Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
Other Sizes |
|
Targets |
β-lactam
|
---|---|
ln Vitro |
Clavulanic acid and ampicillin exhibit synergistic antibacterial activity (against β-lactamase-producing organisms)[2].
Ab11 and Ab51 strains are inhibited by clavulanic acid at MICs of 2–8 μg/mL[3]. |
ln Vivo |
An A. baumannii-infected C57BL/6 mouse pneumonia model's lung bacterial load is reduced by clavulanic acid (13 mg/kg, i.p.)[3].
Clavulanic acid (13 mg/kg, i.p.) in the pneumonia model of Ab51-infected C57BL/6 mice exhibits a t1/2 of 6.69 h and an AUC of 4.03 mg·h/L[3].
Rat models of paw edema induced by carrageenan (HY-125474) exhibit anti-inflammatory effects when treated with clavulanic acid (100–300 mg/kg, i.p.)[4]. |
References |
Molecular Formula |
C8H9NO5
|
---|---|
Molecular Weight |
199.16
|
Exact Mass |
199.0481
|
CAS # |
58001-44-8
|
Related CAS # |
Potassium clavulanate cellulose;Clavulanate lithium;61177-44-4;Clavulanate potassium;61177-45-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1[C@@H]2N(C1=O)[C@H](/C(=C/CO)/O2)C(=O)O
|
InChi Key |
HZZVJAQRINQKSD-PBFISZAISA-N
|
InChi Code |
InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1
|
Chemical Name |
(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
|
Synonyms |
Clavulanate; Acide clavulanique; Acido clavulanico; Clavulansaeure; Antibiotic MM 14151; acidum clavulanicum;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~13.89 mg/mL (~69.74 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10% DMSO+90% (20% SBE-β-CD in Saline): ≥ 2.5 mg/mL (12.55 mM) Solubility in Formulation 4: 12.5 mg/mL (62.76 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.0211 mL | 25.1054 mL | 50.2109 mL | |
5 mM | 1.0042 mL | 5.0211 mL | 10.0422 mL | |
10 mM | 0.5021 mL | 2.5105 mL | 5.0211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Time-kill curves of CLA and IPM against strains Ab11 and Ab51. The control has no antibiotic.Antimicrob Agents Chemother. 2009 Oct;53(10):4298-304. td> |
CLA concentrations during the time-kill curves with strains Ab11 and Ab51.Antimicrob Agents Chemother. 2009 Oct;53(10):4298-304. td> |
Serum CLA and IPM concentrations. CLA was administered at 13 mg/kg, and IPM was administered at 30 mg/kg.Antimicrob Agents Chemother. 2009 Oct;53(10):4298-304. td> |
Effect of antibiotic therapy with CLA or IPM on the clearance of A. baumannii from mouse lungs. *, P ≤ 0.001 relative to the control group (by ANOVA and Tukey and Dunnett post hoc tests).Antimicrob Agents Chemother. 2009 Oct;53(10):4298-304. td> |